Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 8/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.44 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071351 | 0.87 | MCHR1 (0.58) | MCHR1HRH3 | |
| SCHEMBL2257602 | 0.83 | SIGMAR1 (0.59) | MCHR1HRH3SIGMAR1 | |
| SCHEMBL2516706 | 0.82 | MCHR1 (0.51) | MCHR1HRH3MAPK1 | |
| SCHEMBL5817187 | 0.79 | ACHE (0.56) | MCHR1HRH3SIGMAR1 | |
| SCHEMBL2514685 | 0.76 | HRH3 (0.52) | MCHR1HRH3MAPK1SIGMAR1 | |
| SCHEMBL3168599 | 0.76 | SIGMAR1 (0.66) | MCHR1MAPK1SIGMAR1 | |
| SCHEMBL5547852 | 0.76 | LMNA (0.61) | MCHR1HRH3MAPK1SIGMAR1 | |
| SCHEMBL5535158 | 0.74 | BCHE (0.62) | MCHR1HRH3SIGMAR1 | |
| SCHEMBL7069901 | 0.73 | KDM4E (0.72) | MAPK1SIGMAR1 | |
| SCHEMBL10407610 | 0.73 | EP300 (0.58) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | MCHR1 585/4885HRH3 16/4885F10 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.